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Abstract
Background—Venous thromboembolism (VTE) affects as many as 1 in 1000 individuals in the 
United States. Although Blacks are disproportionately affected by VTE, few genetic risk factors 
have been identified in this population. The inducible heme oxygenase-1 (HMOX1) gene encodes 
a key cytoprotective enzyme with anti-inflammatory, antioxidant and anticoagulant activity acting 
in the vascular system. A (GT)n microsatellite located in the promoter of the HMOX1 gene 
influences the level of response.
Methods and Results—Using the Genetic Attributes and Thrombosis Epidemiology (GATE) 
study, we examined the association between HMOX1 repeat length and VTE events in 883 Black 
and 927 White patients and matched controls. We found no association between HMOX1 
genotypes and VTE in Whites. However, in Black patients, carrying two long (L) alleles (≥34 
repeats) was significantly associated with provoked (odds ratio (OR) 1.86, 95% confidence 
interval (CI): 1.19–2.90) or recurrent (OR 3.13, 95% CI: 1.77–5.53) VTE events.
Conclusions—We have demonstrated for the first time an association between genetic variation 
in HMOX1, and VTE in Blacks. Our results support a key role for the heme oxygenase system in 
protecting patients at increased risk for thrombosis and suggest a potential mechanism for targeted 
screening and intervention.
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Introduction
Venous thromboembolism (VTE) is a chronic, sometimes fatal disease with significant 
public health impact worldwide [1]. Defined clinically as inappropriate clotting of the blood 
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presenting as either deep vein thrombosis (DVT), pulmonary embolism (PE) or both, VTE is 
estimated to affect approximately 1 in 1000 individuals per year in the U.S. alone [2, 3]. 
Surviving VTE patients also face increased risk of recurrent thromboembolism and 
significant morbidity with post-thrombotic syndrome symptoms including pain, swelling 
and leg ulceration from venous reflux and post-thrombotic syndrome [4, 5]. In spite of the 
high burden of VTE, much of the underlying etiology remains unexplained.
The inflammatory process is increasingly being recognized as an important mechanism 
regulating thrombus formation and resolution [6, 7]. Biomarkers for inflammation, including 
C-reactive protein, have been reported to be increased in patients with VTE [8, 9]. The lysis 
of red blood cells (RBCs) abundant in the early thrombus may contribute to further 
endothelial dysfunction and thrombus propagation through cascading RBC lysis. Free heme 
from the released hemoglobin is highly inflammatory and a major source of oxidative stress 
on the endothelium [7, 10, 11].
Heme oxygenase-1 (HO-1), the inducible isoform responsible for the catabolism of heme, is 
a key cytoprotective enzyme acting in the vascular system [12]. HO-1 is upregulated in 
response to stress and is induced by stimuli including heme, oxidants, hypoxia, and certain 
cytokines. The anti-inflammatory, antioxidant and anti-apoptotic effects of HO-1 can be 
mediated through the two-fold effects of the degradation of heme. First, the removal of 
heme, which is very oxidative, prevents it from damaging cells and promoting programmed 
cell death. Second, the products of heme catabolism by HO-1, namely ferrous iron, carbon 
monoxide and biliverdin, are themselves cytoprotective acting as signaling or upstream 
molecules in anti-inflammatory, antioxidant pathways in the endothelium [12, 13].
Recent studies suggest that HO-1 activity may play an important role in VTE. Knockout 
mice which do not express HO-1 have been shown to have an enhanced inflammatory 
response and significantly impaired resolution of experimentally induced venous thrombosis 
[14]. Humans carry a (GT)n microsatellite (rs3074372) located in the promoter of the heme 
oxygenase-1 (HMOX1) gene that may influence the level of HO-1 response whereby 
individuals with lower numbers of repeats have higher inducible expression [15]. Indeed, 
Austrian VTE patients who carried longer HMOX1 (GT)n repeat lengths have been reported 
to be at an increased risk of recurrence [16].
No studies to date have explored the role of HO-1 in first VTE in Whites or in any VTE in 
Black populations, where, in spite of elevated risk, limited data on genetic factors for 
thrombosis exists [17, 18]. The Genetic Attributes and Thrombosis Epidemiology (GATE) 
study provides a unique opportunity to simultaneously determine contribution of genetic 
polymorphisms to VTE in both Black and White populations [17]. Using this case-control 
study in which both of these groups are nearly equally represented, we examine associations 
between HMOX1 (GT)n repeat length and various types of VTE events.
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Study population and clinical definitions
The GATE study design and characteristics have been previously described in detail [17, 
18]. Briefly, cases were adult patients 18–70 years of age who were admitted to one of two 
university hospitals in Atlanta, Georgia during between 1998 and 2005 and were diagnosed 
with a first or recurrent VTE. Cases were identified by review of medical charts of patients 
receiving unfractionated or low-molecular-weight heparin. DVT was confirmed by Doppler 
ultrasonography, computed tomography (CT), magnetic resonance imaging, or contrast 
venography. Confirmation of PE was made by positive angiogram, ventilation–perfusion 
lung scan, or CT. Patients with severe illness or with cognitive deficits were excluded [17].
Controls were selected from a list of patients who visited a university affiliated primary care 
clinic between 1997 and 2000; those currently taking anti-coagulant therapy or who had a 
history of VTE were ineligible. Similar to cases, controls with severe illness or cognitive 
defects were also excluded. Controls were frequency matched to cases on age, gender and 
race [17]. All self-identified Black and White individuals with DNA available for 
genotyping were included in the present analysis.
Provoked cases were distinguished from idiopathic as VTE arising within 1 week of any of 
the following settings: with cancer, in conjunction with the placement of a central line, 
during or after attendance in the intensive care unit, during or after a pregnancy, or after 
surgery, an injury, or prolonged immobilization within the previous 4 weeks. The mean time 
between the trigger for the event and its diagnosis was less than 1 week for provoked cases. 
First events were also distinguished from recurrent by self-reported history of VTE [18].
DNA analysis
Polymerase chain reaction (PCR) fragment size analysis was used to determine HMOX1 
promoter (GT)n dinucleotide repeat (rs3074372) length, using a FAM labeled forward 
primer, AGA GCC TGC AGC TTC TCA GA and an unlabeled reverse primer, ACA AAG 
TCT GGC CAT AGG AC. Amplification was performed in a 10 µl reaction (final 
concentration 1× GeneAmp® PCR buffer with MgCl2 (Applied Biosystems, Foster City, 
CA), 0.5 mM dNTPs, 0.625 µM primers (each), 5% dimethyl sulfoxide (DMSO), 0.25 U 
Amplitaq (Applied Biosystems). The PCR conditions used for labeling were 96°C for 10 
minutes, 40 cycles (92°C for 30 seconds; 51°C for 30 seconds; 72°C for 30 seconds) and 
72°C for 7 minutes, followed by a 4°C hold. Labeled products were run with an internal size 
standard (GeneScan™ −500 LIZ®) in Hi-Di™ Formamide on a 3730 DNA Analyzer, and 
fragment size was determined using GeneMapper® Software Version 4.0 software (Applied 
Biosystems).
Approximately 5% of samples were validated by DNA sequence analysis to confirm 
HMOX1 repeat length. Initial fragment amplification was performed as described above for 
fragment analysis substituting unlabeled primers. Following an ExoSap-IT (Affymetrix, 
Santa Clara, CA) reaction to remove unused primers and nucleotides, BigDye® Terminator 
v1.1 Cycle Sequencing Kit (Applied Biosystems) was used to prepare the samples for 
automated sequencing according to the manufacturer’s recommendations. Sequencing 
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reactions were further cleaned up by ethanol precipitation and re-suspended in Hi-Di™ 
Formamide. Samples were then run on an ABI 3730 DNA Analyzer, and sequences were 
reviewed using Sequencing Analysis 5.2 (Applied Biosystems).
(GT)n repeat classification
For initial analyses, the observed HMOX1 (GT)n repeat sizes were divided into three allele 
classes, short (S) with 25 or fewer repeats, medium (M) with 26 to 33 repeats, and long (L) 
with 34 or more repeats. To model the effect of carrying the longer “risk” alleles in logistic 
regression analyses, small and medium alleles were grouped together and compared to long 
(L) alleles with 34 or more repeats.
Statistical analysis
Differences in the distribution of demographic and clinical characteristics and repeat length 
categories between cases and controls were assessed using two-tailed chi-square tests, t-
tests, and Fisher’s exact tests, where appropriate. Conditional logistic regression was used to 
calculate odds ratios and 95% confidence intervals for the association between repeat length 
(L/L vs. other) and VTE among Blacks, conditioning on age and sex. Because no White 
cases had the L/L genotype, Whites were omitted from the regression analyses. The 10% 
change in effect estimate criterion was used to evaluate potential confounders (diabetes, 
obesity, high blood pressure, current smoker, family history of VTE, history of cancer, 
sickle cell disease, and Factor V Leiden). As such, the crude odds ratio was compared with 
the adjusted odds ratio for each variable individually, and those variables associated with a 
difference of 10% or more were considered confounders [19]. However, after applying the 
criterion, none of the covariates remained in the final model; thus, crude odds ratios are 
presented. SAS 9.2 software (SAS Institute, Cary, NC) was used for all analyses.
Results
Clinical characteristics
Demographic and clinical characteristics for VTE cases and controls included in this study 
are reported in Table 1. Results are reported by race, and VTE event types are dichotomized 
as follows: DVT only vs. PE and/or DVT; first occurrence vs. recurrent; and provoked vs. 
idiopathic. Regardless of race, the frequency of diabetes, family history of VTE, and history 
of cancer was higher in cases than controls. Among whites, significantly greater proportions 
of cases were obese, had high blood pressure, were current smokers and carried the Factor V 
Leiden mutation compared with controls. For both race subgroups, more than 60% of VTE 
events were classified as DVT only. The proportion of provoked VTE was 62% for White 
cases and 58% for Black cases, and the proportion of recurrent VTE was 24% for White 
cases and 20% for Black cases.
HMOX1 (GT)n repeat distribution
The HMOX1 (GT)n repeat was highly polymorphic, and the distribution of alleles differed 
by race with greater variation observed in the Black population (Figure 1). Overall, we 
observed 28 different alleles with the number of dinucleotide repeats varying from 13 to 45. 
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In addition to peaks at 23 and 30 repeats, we observed a third peak at 39 repeats in the Black 
population that was absent from the White population.
HMOX1 (GT)n repeat and VTE
For initial comparisons, the observed HMOX1 (GT)n repeat sizes were grouped into three 
allele classes: short (S) with 25 or fewer repeats, medium (M) with 26 to 33 repeats, and 
long (L) with 34 or more repeats. The distribution of the 6 possible genotype classes in cases 
and controls are shown by race in Table 2. We found no significant association between 
HMOX1 genotypes and VTE in Whites. However, the distribution of HMOX1 genotype 
classes was significantly different between Black cases and controls, with an increased 
frequency of L/L in all patients with VTE (Table 2A). When patients were stratified by 
event type, this effect became much more pronounced with an increased frequency of L/L 
genotypes in patients with provoked as well as recurrent VTE (Tables 2C and 2E). HMOX1 
allele distribution was not significantly different in Black cases with idiopathic or first VTE 
events compared to controls (Tables 2B and 2D). The relationship between genetic variation 
in HMOX1 and pulmonary embolism alone was not separately assessed due to the limited 
number of patients presenting with PE only.
For logistic regression modeling, we tested a recessive genetic effect, comparing individuals 
with L/L genotypes to all other genotype classes (Table 3). Homozygous L/L individuals 
were rare in the White population with only one control having this genotype; thus we were 
unable to model this characteristic in Whites. For Black patients, L/L genotype was 
significantly associated with provoked (odds ratio (OR) 1.86, 95% confidence interval (CI): 
1.19–2.90) or recurrent (OR 3.13, 95% CI: 1.77–5.53) VTE events. The association between 
genotype and idiopathic or first VTE events did not reach statistical significance in these 
cases, although both ORs were elevated for the L/L genotype.
To explore the difference in findings by VTE subtype post-hoc case-case analyses were 
conducted for the Black cases only (n = 440). In conditional logistic regression models 
assessing differences in the L/L genotype for provoked versus idiopathic, the association 
was not statistically significant (OR 1.29, 95% CI: 0.76–2.19). However, the L/L genotype 
was significantly associated with recurrent VTE compared with first VTE (OR 2.47, 95% 
CI: 1.40–4.36, p=.002).
Discussion
Blacks are disproportionately affected by VTE, yet there remains limited data on the 
etiology [20]. Family history of VTE has been shown to increase risk; however, other than 
one report of sickle cell trait, no genetic risk factors have been well characterized in Blacks 
[18, 21]. In the present study, we demonstrated a novel association between genetic 
variation in the vascular cytoprotective enzyme, HO-1, and VTE in Blacks. Additionally, 
this study is the first to test (GT)n repeat alleles for associations with first VTE and 
idiopathic versus provoked events in any population. Specifically, we found that Black 
patients with L/L HMOX1 promoter (GT)n repeat genotypes were at significantly increased 
risk for provoked as well as recurrent VTE.
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A robust heme oxygenase response may be particularly important to protect individuals with 
VTE disease by inhibiting thrombus formation or expansion induced by free heme and 
redox-active iron. Free pro-oxidative iron and heme-containing moieties in the bloodstream 
are highly toxic to the vasculature and can lead to endothelial dysfunction and vascular 
disease [10, 22, 23]. Interestingly, recent studies have demonstrated an important role of red 
blood cell hemolysis and hemoglobin oxidation in promoting iron-induced vascular injury 
and thrombosis in an ex vivo model system [11]. Further, these authors provided evidence 
that free hemoglobin may also contribute to thrombus development by exacerbating red 
blood cell lysis and further driving a damaging oxidative cycle [11].
Inducible HO-1 is the rate limiting enzyme responsible for the removal of damaging, highly 
oxidative free heme from the circulation. Additionally, the products of the degradation of 
heme, ionic iron, CO and biliverdin, or their immediate downstream products also contribute 
to an anti-oxidative, anti-inflammatory state and have anti-thrombotic activity [12, 24, 25]. 
DNA polymorphisms which impair or reduce HO-1 response may therefore lead to 
increased risk of endothelial dysfunction and vascular disease, including resolution of 
venous thrombosis [14]. Human patients with shorter HMOX1 promoter (GT)n repeat alleles 
might benefit by having a stronger inducible heme oxygenase response [15, 26], and indeed, 
long alleles were associated with increased risk of recurrent VTE in the only other study to 
date to examine the role of this polymorphism in VTE [16].
The distribution of allele lengths differed dramatically between Blacks and Whites in our 
study and may help to explain the difference in the incidence of VTE in the two populations 
in the U.S. Whites were significantly less likely to carry longer “risk” alleles, and the 
prominent 23 and 30 repeat sizes accounted for more than half of the alleles present. Unlike 
Mustafa and colleagues who examine risk of recurrence in a case-only series of patients with 
spontaneous first VTE [16], we found no association between HMOX1 (GT)n repeat length 
and VTE in White patients in our case-control study. The discrepancy in findings may be 
due to differences in recurrent VTE sample size and analytical approaches. The frequency of 
long alleles was similar in both studies, and a sample size of over 850 White patients was 
necessary to identify only 3 individuals with L/L genotypes [16]. Because of this rarity of 
long alleles, a larger sample size will be necessary to clarify the role of this polymorphism in 
thrombotic disease in Whites.
In contrast, we identified a pattern of greater genetic variation that was shifted toward longer 
repeats in Blacks, and more than one-quarter of the (GT)n alleles were 34 repeats or greater. 
This increased prevalence of long repeat alleles was similar to that seen in the few studies to 
date characterizing this microsatellite polymorphism in individuals with African ancestry 
[27]. We found a significant association in these patients with long allele length and all VTE 
that became more pronounced in the provoked and recurrent categories when patients were 
stratified by event type. Although the ORs were elevated for idiopathic or first VTE events, 
the association with L/L genotype did not reach statistical significance in Blacks. It is 
intriguing that our exploratory case-only analysis of L/L genotype with recurrent versus first 
VTE was significant in Blacks. However, our results are based on a relatively small number 
of cases, and additional studies will be necessary to verify whether the heme oxygenase 
response plays a differential role in the etiologies of these subtypes.
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Our results support a key role for the heme oxygenase system in protecting patients at 
increased risk for thrombosis. Our findings also suggest a potential mechanism for targeted 
screening and intervention, particularly since the risk-conferring alleles are relatively 
common in Blacks. For example, additional or extended thromboprophylactic treatment 
might be beneficial in patients at risk of provoked VTE or to prevent recurrence in those 
individuals that also carry long HMOX1 (GT)n alleles.
Our findings are subject to several limitations. First, the low prevalence of L/L genotype in 
White cases precluded the evaluation of the association between repeat length and VTE in 
the White population. Second, the cases for the GATE study represented only those patients 
who were hospitalized and did not include those who were treated for VTE in outpatient 
settings. Findings from recent studies indicate that 50–73% of patients with VTE presented 
in an outpatient setting [28, 29]; therefore our findings are only representative of individuals 
with VTE severe enough to require hospitalization. Finally, although longer HMOX1 (GT)n 
promoter repeats have been associated with impaired inducible heme oxygenase [15, 27, 
30], no functional measurements of expression levels or enzyme activity were available in 
our patient samples.
In summary, we demonstrated a novel association with genetic variation in the heme 
oxygenase system in Blacks, a population disproportionately affected by VTE in the United 
States. The odds of carrying L/L HMOX1 promoter (GT)n repeat genotypes were 
approximately two and three times greater in patients with provoked and recurrent VTE, 
respectively, compared to controls. Our findings support a key role for the heme oxygenase 
system in protecting patients at increased risk for thrombosis and suggest a novel approach 
for future targeted screening and intervention. Additional clinical and functional studies will 
be necessary to confirm our findings and further elucidate the role of impaired heme 
oxygenase response in patients at risk for VTE.
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Figure 1. HMOX1 (GT)n repeat distribution among Genetic Attributes and Thrombosis 
Epidemiology (GATE) study participants by race
Allele lengths were scored as number of dinucleotide repeats and ranged from 13 to 45 
repeats. ‘Small’ is defined as ≤25 repeats; ‘Medium’ is defined as 26–33 repeats; and ‘Long’ 
is defined as ≥34 repeats. Distribution of alleles is shown for A) 927 White and B) 883 
Black patients and matched controls.
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Table 3





n (%) Odds Ratio† 95% CI
A. All VTE
S*/S*+S*/L 369 (83.9) 398 (89.8) REF
L/L 71 (16.1) 45 (10.2) 1.69 1.13–2.52
B. Idiopathic VTE
S*/S*+S*/L 160 (86.0) 398 (89.8) REF
L/L 26 (14.0) 45 (10.2) 1.36 0.80–2.30
C. Provoked VTE
S*/S*+S*/L 209 (82.3) 398 (89.8) REF
L/L 45 (17.7) 45 (10.2) 1.86 1.19–2.90
D. First event
S*/S*+S*/L 306 (86.7) 398 (89.8) REF
L/L 47 (13.3) 45 (10.2) 1.36 0.88–2.10
E. Recurrent VTE
S*/S*+S*/L 63 (72.4) 398 (89.8) REF
L/L 24 (27.6) 45 (10.2) 3.13 1.77–5.53
*
Findings for Whites were not modeled due to lack of cases with L/L genotype.
‡
‘S*’ is ≤33, and ‘L’ is ≥34.
†
Logistic regression models conditioned on age (≤40, 41–50, 51–60, 60+) and sex.
Thromb Res. Author manuscript; available in PMC 2015 April 07.
